May 2014

Contents

Editorial

• May/June 2014: Volume 15 Number 5/6

Conference reports

• 49th Annual Meeting of the European Association for the Study of the Liver (EASL 2014), 9-13 April 2014, London

• Activists protest the price of sofosbuvir: “So-Valdi, So-Expensive” – UK access already rationed

• EASL 2014: summary of interferon-free HCV studies with new DAAs

• WHO launch treatment guidelines for hepatitis C (2014)

• 3rd Joint Conference of BHIVA/BASHH, 1-4 April 2014, Liverpool

• 50% of UK seroconverters start ART within 1.4 years of infection: treating during primary infection should be a patient choice

• PIVOT study: further analysis from five-year PI/r monotherapy strategy study

• Sexually transmitted HCV in HIV positive and negative gay men

• Annual HCV testing and use of core antigen to reduce costs and increase diagnosis during acute HCV

• HIV positive attitudes to involvement as donors and recipients in organ transplant programmes

• 21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston

• Pharmacokinetics of antiretrovirals in pregnancy

• Better virologic outcomes with efavirenz vs lopinavir/ritonavir in pregnant women and no difference in risk of preterm birth

• Once daily lopinavir/ritonavir not recommended for routine use in children and adolescents

• Early antiretroviral treatment in infants

• Hospitalisation among elite controllers

• Catching up with pathogenesis and cure research from CROI 2014

Guidelines

• US adult treatment guidelines updated (May 2014)

• US PrEP guidelines (May 2014): emphasis on broad access may miss optimal use by people at highest risk

Side effects

• No increase death rate in HIV positive people with renal dysfunction receiving tenofovir in Zambia

Hepatitis coinfection

• EMA fast-track sofosbuvir/ledipasvir FDC for hepatitis C

Cure research

• Reassessing the role of HDAC inhibitors in cure research

• More on the links between the CD4/CD8 ratio, immunological perturbations, and risk of illness and death

Basic science and immunology

• Incidence of HIV dual infections in US men who have sex with men

Other news

• Partner 2 study extended for gay couples

• TAILoR Study: telmisartan to reduce risk of insulin resistance: potential role for lipodystrophy

• SCART study: selumetinib as potential treatment for HIV-related KS

• Scotland agrees to free HIV treatment, regardless of residency status

On the web

• Community reports and briefings

PDFs

• Volume 15 Number 5/6 May/June 2014 PDF